|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cyprotex (COTXF.PK) Results For The Year Ended 31 December 2009
3/17/2010 3:03:23 PM
Cyprotex PLC (AIM:CRX), the drug discovery technology and information company, today reports its final results for the year ended 31 December 2009. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market.
Financial Highlights
• Revenues hit £5 million for second successive year at £5.00 million (2008: £5.18 million)
• Second year of profitability with operating profits at £0.46 million (2008: £0.57 million)
• Cash and cash equivalents up £0.49 million at £2.07 million
• Strong positive cash flow from operations at £0.90 million up £0.36 million.
Operational Highlights
• Doubled number of strategic customers in 2009 (being customers contributing annual revenues in excess of £250,000 each) from three to six
• Won over twenty new customers
• Newly internally developed assays generated over £300,000 of revenues
• Investment in laboratory space and state of the art mass spectrometer secured new strategic customer
• Strategic alliance announced with Sygnature Chemical Services Limited, a leading provider of medicinal and computational chemistry services
• Launched Cloe® Gateway, our new web based portal for access to Cyprotex services
Steve Harris, Chairman of Cyprotex PLC, said:
“Cyprotex’s results represent an impressive performance against a very difficult market currently for the pre-clinical CRO sector. Cyprotex continues to attract new customers, expand its offerings and is investing in new laboratories to service both the ADME and pre-clinical toxicology markets”
|
|
|
|
|
|
|
|
|
|
|